Table 1 Baseline characteristics
From: Predictors of response to fixed-dose vasopressin in adult patients with septic shock
Characteristic | Total (N = 938) | Non-responders (N = 512) | Responders (N = 426) | P value |
|---|---|---|---|---|
Characteristics at ICU admission | ||||
Age, years | 62 ± 14 | 61 ± 15 | 62 ± 14 | 0.17 |
Male, n (%) | 493 (52.6) | 272 (53.1) | 221 (51.9) | 0.70 |
Race, n (%) | 0.10 | |||
Caucasian | 652 (69.5) | 357 (69.7) | 295 (69.2) | |
African American | 241 (25.7) | 124 (24.2) | 117 (27.5) | |
Other | 45 (4.8) | 31 (6.1) | 14 (3.3) | |
ICU type, n (%) | 0.06 | |||
Medical | 712 (75.9) | 401 (78.3) | 311 (73.0) | |
Neurological | 65 (6.9) | 27 (5.3) | 38 (8.9) | |
Surgical | 161 (17.2) | 84 (16.4) | 77 (18.1) | |
Weight, kg | 90.5 ± 34.0 | 92.0 ± 37.1 | 88.6 ± 29.9 | 0.13 |
BMI, kg/m2 | 31.5 ± 11.7 | 31.9 ± 12.6 | 31.0 ± 10.4 | 0.22 |
ESRD, n (%) | 119 (12.7) | 58 (11.3) | 61 (14.3) | 0.17 |
APACHE III | 106 ± 34 | 107 ± 36 | 104 ± 30 | 0.09 |
APS | 90 ± 32 | 92 ± 35 | 88 ± 29 | 0.14 |
Comorbid conditions, n (%) | ||||
Diabetes mellitus | 286 (30.5) | 152 (29.7) | 134 (31.5) | 0.56 |
Hepatic failure | 160 (17.1) | 99 (19.3) | 61 (14.3) | 0.04 |
Immune suppression | 196 (20.9) | 109 (21.3) | 87 (20.4) | 0.75 |
Leukemia/myeloma | 65 (6.9) | 38 (7.4) | 27 (6.3) | 0.52 |
Moderate COPD | 13 (1.4) | 9 (1.8) | 4 (0.9) | 0.45 |
Severe COPD | 85 (9.1) | 42 (8.2) | 43 (10.1) | 0.45 |
No chronic health issues, n (%) | 232 (24.7) | 118 (23.0) | 114 (26.8) | 0.19 |
Characteristics at time of AVP initiation | ||||
Appropriate antibiotics, n (%)a | 887 (94.6) | 487 (95.1) | 400 (93.9) | 0.41 |
Fluids prior to AVP, mL/kg | 30.7 ± 34.4 | 30.6 ± 35.1 | 30.8 ± 33.6 | 0.95 |
MAP, mmHg | 67 ± 12 | 65 ± 12 | 69 ± 12 | < 0.001 |
Lactate, mmol/L | 4.8 ± 4.4 | 5.4 ± 4.8 | 4.0 ± 3.6 | < 0.001 |
SOFA score | 13 ± 4 | 12 ± 3 | 13 ± 4 | 0.49 |
Total CA dose | ||||
mcg/min | 28.2 ± 19.9 | 27.8 ± 21.9 | 28.6 ± 17.3 | 0.54 |
mcg/kg/min | 0.34 ± 0.26 | 0.33 ± 0.27 | 0.35 ± 0.25 | 0.18 |
Catecholamine agent, n (%) | ||||
Norepinephrine | 937 (99.9) | 511 (99.8) | 426 (100.0) | 0.99 |
Phenylephrine | 66 (7.0) | 31 (6.1) | 35 (8.2) | 0.20 |
Epinephrine | 25 (2.7) | 11 (2.1) | 14 (3.3) | 0.28 |
Dopamine | 4 (0.4) | 2 (0.4) | 2 (0.5) | 0.99 |
AVP dose | ||||
Units/min | 0.0314 ± 0.0063 | 0.0317 ± 0.0064 | 0.0312 ± 0.0062 | 0.24 |
Units/kg/h | 0.0226 ± 0.0084 | 0.0224 ± 0.0084 | 0.0227 ± 0.0083 | 0.66 |
Corticosteroids, n (%) | 571 (60.9) | 320 (62.5) | 251 (58.9) | 0.26 |
AKI, n (%) | 0.21 | |||
Risk | 79 (8.4) | 50 (9.8) | 29 (6.8) | |
Injury | 32 (3.4) | 21 (4.1) | 11 (2.6) | |
Failure | 142 (15.1) | 75 (14.6) | 67 (15.7) | |
Loss | 0 (0) | 0 (0) | 0 (0) | |
CRRT, n (%) | 159 (17.0) | 81 (15.8) | 78 (18.3) | 0.31 |